Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib
2010

Circulating Endothelial Cells as Predictors in Renal Cell Carcinoma Treatment

Sample size: 26 publication Evidence: moderate

Author Information

Author(s): Viktor Gruenwald, Gernot Beutel, Susanne Schuch-Jantsch, Christoph Reuter, Philipp Ivanyi, Arnold Ganser, Marion Haubitz

Primary Institution: Hannover Medical School

Hypothesis

Can circulating endothelial cells (CEC) serve as a predictive biomarker for tumor response in renal cell carcinoma patients treated with sunitinib?

Conclusion

The study suggests that an early increase in circulating endothelial cells is associated with a better response to sunitinib treatment in renal cell carcinoma patients.

Supporting Evidence

  • Patients with metastatic RCC had significantly higher CEC levels compared to normal controls.
  • Sunitinib treatment led to an increase in CEC in patients with progression-free survival above the median.
  • Monocyte counts decreased significantly during sunitinib treatment, indicating target inhibition.

Takeaway

Doctors can check the number of special cells in the blood to see if a cancer treatment is working early on.

Methodology

The study analyzed circulating endothelial cells, monocytes, and soluble VEGFR-2 in 26 patients with metastatic RCC receiving sunitinib treatment.

Potential Biases

Potential biases may arise from the lack of external validation and the single-institution study design.

Limitations

The small sample size limits the generalizability of the findings.

Participant Demographics

The study included 26 patients with a mean age of 62 years, consisting of 15 males and 11 females.

Statistical Information

P-Value

0.0001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2407-10-695

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication